Moffitt Cancer Center Executive Leadership

patrick-hwu-profile

Patrick Hwu, MD

President and CEO

Patrick Hwu, MD, is the president and CEO of Moffitt Cancer Center, one of the nation’s leading cancer hospitals and the only National Cancer Institute-designated comprehensive cancer center based in Florida.

As an internationally recognized tumor immunologist, Dr. Hwu has led pioneering research and clinical efforts to better understand the interactions between tumors and the immune system. He helped launch the field of gene modified T cells, publishing research on the first chimeric antigen receptor directed against cancer. His work focuses on vaccines, adoptive T-cell therapies and immune resistance. An internationally recognized physician scientist, Hwu has a proven track record leading collaborative teams to make breakthroughs in science while improving cancer outcomes for cancer patients.

Prior to joining Moffitt, Dr. Hwu was the head of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, where he held various leadership roles for 17 years. In 2003, he was recruited as the first chairman of the Department of Melanoma Medical Oncology. He was also the associate director of the Center for Cancer Immunology Research (2004) and chair of the Department of Sarcoma Medical Oncology (2012).

Dr. Hwu earned his medical degree from The Medical College of Pennsylvania. He served as a house officer in Internal Medicine at The Johns Hopkins Hospital and completed a fellowship in oncology at the National Cancer Institute, where he worked as a principal investigator leading tumor immunology studies.


Related Stories

Moffitt Cancer Center Names Patrick Hwu, M.D., as President and CEO
Tumor immunologist with 33 years of oncology experience begins tenure Nov. 10

Research Programs
Moffitt's five research programs, supported in part by the Cancer Center Support Grant (CCSG), consist of integrative teams working together to tackle the complexity of cancer.

Speeding Up Cellular Immunotherapy
New ‘off the shelf’ CAR T product shows promise in phase 1 study